PC model disentangles puzzle behind serious aggravation in individuals with COVID-19 Kumar Jeetendra | September 29, 2020 A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular arrangement and arrangement of the SARS-CoV-2 spike protein–part of the virus that causes COVID-19–could be behind the inflammatory syndrome cropping up …
Russia to start Phase III preliminaries of second COVID-19 antibody in November-December: Report Kumar Jeetendra | October 2, 2020 Russia begins Phase III trials of a second possible vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer security watchdog Rospotrebnadzor as saying on October 2. Early-stage clinical trials for the vaccine have been completed on Wednesday.
High-dosage favipiravir ‘strong’ against COVID-19, HCQ totally incapable: Study Kumar Jeetendra | October 11, 2020 Research conducted at the KU Leuven Rega Institute in Belgium has found that the antimalarial drug hydroxychloroquine (HCQ) doesn’t limit the multiplication of the novel coronavirus. However, a very high dose of the flu drug favipiravir does have antiviral efficacy, according to their results. The researchers gave the hamsters either hydroxychloroquine or favipiravir for four …
Johnson and Johnson stops preliminaries because of unexplained ailment in member Kumar Jeetendra | October 13, 2020 Johnson & Johnson said on October 12 it has temporarily paused clinical trials of its own COVID-19 vaccine candidate because of an unexplained illness in a research participant. In a statement, the company said that the participant’s illness has been reviewed and assessed by an independent data and safety monitoring board, and its clinical and …
Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
Healthcare professionals experience mental wellness issues during and after pandemics Kumar Jeetendra | October 16, 2020 Mental health problems such as Post-Traumatic Stress Disorder, anxiety and depression are common among healthcare staff during and immediately after pandemics — according to new research from the University of East Anglia. Researchers investigated how treating patients in previous pandemics like SARS and MERS affected the mental health of front-line staff. They found that nearly …
Expectation of COVID-19 immunization arrangement in UK by New Year: Report Kumar Jeetendra | October 18, 2020 One of the UK’s senior-most medical chiefs has indicated that a vaccine against COVID-19 could be ready to be deployed by the start of the New Year, according to a media report on Sunday. In India, the vaccine has a Serum Institute of India tie-up since it undergoes trials. “We are not light years away …
Oxford University says COVID-19 patients experience symptoms months subsequent to contracting virus Kumar Jeetendra | October 19, 2020 Britain’s Oxford University said on Monday first findings from a study on the long term effect of COVID-19 has discovered a lot of patients discharged from hospitals still experience symptoms of breathlessness, fatigue, depression and anxiety two to three months after contracting the virus. The scientists detected abnormalities in many organs and believe persistent inflammation …
CBD could lessen lung harm brought about by COVID-19 Kumar Jeetendra | October 19, 2020 One way CBD appears to reduce the”cytokine storm” that damages the lungs and kills many individuals with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is proven to reduce inflammation and whose levels are dramatically reduced in the face of this storm. Dental College of Georgia and Medical …
Researchers propose that antimalarial medications could be repurposed to treat COVID-19 Kumar Jeetendra | October 20, 2020 An international group of researchers believe there is enough evidence that anti-malarial drugs could be repurposed to treat COVID-19 and they need to be evaluated for efficacy in clinical trials. The review article, published online in Trends in Parasitology, summarizes the evidence for its antiviral and anti-inflammatory properties of particular anti-malarial drugs which could play …
US preliminary of AstraZeneca COVID-19 immunization may continue this week: Sources Kumar Jeetendra | October 21, 2020 AstraZeneca Plc’s COVID-19 vaccine trial in the United States is expected to resume as early as this week following the U.S. Food and Drug Administration completed its review of a severe illness in a study participant, four sources told Reuters. AstraZeneca’s large, late-stage U.S. trial was on hold since Sept. 6, following a participant at …
SARS-CoV-2 Antibodies and Antigens for Diagnostic Kit Development Kumar Jeetendra | October 22, 2020 AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits. While RT-PCR diagnostic kits has provided fast and sensitive COVID-19 case confirmation, the technique suffers from some inherent drawbacks that limit …
